ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic he… Read more
ViroGates A/S (VIRO) - Net Assets
Latest net assets as of September 2025: Dkr2.83 Million DKK
Based on the latest financial reports, ViroGates A/S (VIRO) has net assets worth Dkr2.83 Million DKK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr14.21 Million) and total liabilities (Dkr11.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr2.83 Million |
| % of Total Assets | 19.95% |
| Annual Growth Rate | -3.14% |
| 5-Year Change | -65.53% |
| 10-Year Change | N/A |
| Growth Volatility | 618.16 |
ViroGates A/S - Net Assets Trend (2015–2024)
This chart illustrates how ViroGates A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ViroGates A/S (2015–2024)
The table below shows the annual net assets of ViroGates A/S from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr10.79 Million | -36.53% |
| 2023-12-31 | Dkr17.01 Million | +5.71% |
| 2022-12-31 | Dkr16.09 Million | -2.06% |
| 2021-12-31 | Dkr16.43 Million | -47.54% |
| 2020-12-31 | Dkr31.31 Million | -25.82% |
| 2019-12-31 | Dkr42.22 Million | -30.81% |
| 2018-12-31 | Dkr61.01 Million | +1935.74% |
| 2017-12-31 | Dkr3.00 Million | -66.64% |
| 2016-12-31 | Dkr8.98 Million | -37.55% |
| 2015-12-31 | Dkr14.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ViroGates A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 74.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr3.06 Million | 28.33% |
| Common Stock | Dkr7.74 Million | 71.67% |
| Total Equity | Dkr10.79 Million | 100.00% |
ViroGates A/S Competitors by Market Cap
The table below lists competitors of ViroGates A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Techcential International Ltd
TWO:6616
|
$4.94 Million |
|
White Energy Company Limited
PINK:WECFF
|
$4.94 Million |
|
Blackbird Critical Metals Corp
OTCQB:BBCMF
|
$4.94 Million |
|
AMEN Properties Inc
PINK:AMEN
|
$4.94 Million |
|
GROUNDS R.EST. NA O.N.
F:AMMN
|
$4.93 Million |
|
Paranapanema S.A
SA:PMAM3
|
$4.93 Million |
|
Smart Gunes Enerjisi Teknolojileri Arastirma Gelistirme Uretim Sanayi ve Ticaret
IS:SMRTG
|
$4.93 Million |
|
Chia Yi Steel Co Ltd
TWO:2067
|
$4.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ViroGates A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,007,000 to 10,795,000, a change of -6,212,000 (-36.5%).
- Net loss of 14,345,000 reduced equity.
- New share issuances of 8,133,000 increased equity.
- Other comprehensive income increased equity by 1,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr-14.35 Million | -132.89% |
| Share Issuances | Dkr8.13 Million | +75.34% |
| Other Comprehensive Income | Dkr1.00K | +0.01% |
| Other Changes | Dkr-1.00K | -0.01% |
| Total Change | Dkr- | -36.53% |
Book Value vs Market Value Analysis
This analysis compares ViroGates A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.60x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.13x to 6.60x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Dkr5.01 | Dkr10.70 | x |
| 2016-12-31 | Dkr3.13 | Dkr10.70 | x |
| 2017-12-31 | Dkr1.23 | Dkr10.70 | x |
| 2018-12-31 | Dkr20.59 | Dkr10.70 | x |
| 2019-12-31 | Dkr10.74 | Dkr10.70 | x |
| 2020-12-31 | Dkr7.83 | Dkr10.70 | x |
| 2021-12-31 | Dkr4.02 | Dkr10.70 | x |
| 2022-12-31 | Dkr3.81 | Dkr10.70 | x |
| 2023-12-31 | Dkr4.91 | Dkr10.70 | x |
| 2024-12-31 | Dkr1.62 | Dkr10.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ViroGates A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -132.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -292.93%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.64x
- Recent ROE (-132.89%) is below the historical average (-79.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -28.29% | -113.28% | 0.21x | 1.21x | Dkr-5.51 Million |
| 2016 | -60.13% | -146.58% | 0.31x | 1.34x | Dkr-6.30 Million |
| 2017 | -199.77% | -245.27% | 0.49x | 1.66x | Dkr-6.29 Million |
| 2018 | -27.84% | -512.24% | 0.05x | 1.04x | Dkr-23.09 Million |
| 2019 | -44.53% | -524.76% | 0.08x | 1.07x | Dkr-23.02 Million |
| 2020 | -59.83% | -349.94% | 0.14x | 1.22x | Dkr-21.87 Million |
| 2021 | -107.53% | -230.71% | 0.38x | 1.23x | Dkr-19.31 Million |
| 2022 | -59.96% | -63.47% | 0.87x | 1.09x | Dkr-11.25 Million |
| 2023 | -71.12% | -173.12% | 0.28x | 1.44x | Dkr-13.80 Million |
| 2024 | -132.89% | -292.93% | 0.28x | 1.64x | Dkr-15.42 Million |
Industry Comparison
This section compares ViroGates A/S's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $233,298,757
- Average return on equity (ROE) among peers: 7.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ViroGates A/S (VIRO) | Dkr2.83 Million | -28.29% | 4.01x | $4.93 Million |
| ChemoMetec A/S (CHEMM) | $-10.06 Million | 0.00% | 0.00x | $951.64 Million |
| Embla Medical hf (EMBLA) | $635.51 Million | 6.69% | 1.09x | $621.39 Million |
| Scandinavian Medical Solutions AS (SMSMED) | $74.45 Million | 16.42% | 1.20x | $4.42K |